Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells.

ABSTRACT:

Background

The skeleton is the first and most common distant metastatic site for breast cancer. Such metastases complicate cancer management, inducing considerable morbidities and decreasing patient survival. Osteomimetism is part of the complex process of osteotropism of breast cancer cells. Recent data indicate that Farnesoid X Receptor (FXR) is involved in the transformation and progression of breast cancer.

Methods

The expression of FXR, Runt-related transcription factor 2 (RUNX2) and bone proteins were evaluated on two tumor cell lines (MCF-7 and MDA-MB-231) by immunohistochemistry, immunofluorescence and western blotting and quantified.

Results

In a series of 81 breast cancer patients who developed distant metastases, we found a strong correlation between FXR ex

SUBMITTER: Absil L 

PROVIDER: S-EPMC7350202 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature